MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sanofi SA Company Profile (EPA:SAN)

Consensus Ratings for Sanofi SA (EPA:SAN) (?)
Ratings Breakdown: 2 Sell Rating(s), 10 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.18)
Consensus Price Target: €87.12

Analysts' Ratings History for Sanofi SA (EPA:SAN)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016Independent Research GmbHSet Price TargetNeutral€77.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Jefferies GroupSet Price TargetNeutral€76.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016BarclaysSet Price TargetBuy€84.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016HSBCSet Price TargetNeutral€81.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/25/2016Morgan StanleySet Price TargetNeutral€90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016Societe GeneraleSet Price TargetBuy€104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016JPMorgan Chase & Co.Set Price TargetSell€77.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Goldman SachsSet Price TargetNeutral€80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2016Berenberg BankSet Price TargetNeutral€93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016S&P Equity ResearchSet Price TargetBuy€85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/10/2015BNP ParibasSet Price TargetSell€80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/30/2015Deutsche BankSet Price TargetBuy€103.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Sanford C. BernsteinSet Price TargetNeutral€91.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Kepler Capital MarketsSet Price TargetNeutral€83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015Credit SuisseSet Price TargetBuy€100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/29/2015Citigroup Inc.Set Price TargetNeutral€99.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Sanofi SA (EPA:SAN)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Sanofi SA (EPA:SAN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Sanofi SA (EPA:SAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Sanofi SA (EPA:SAN)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Sanofi SA (EPA:SAN)
DateHeadline
07/01/16 09:02 AMHC Stocks Buzzer: Baxter International Inc (NYSE:BAX), Sanofi SA (ADR) (NYSE:SNY) - share market updates (press release)
06/30/16 09:02 AMNotable Stocks to Watch: Sanofi SA (NYSE:SNY), LyondellBasell Industries NV (NYSE:LYB) - NYSE Journal (press release)
06/30/16 09:02 AMHC Stocks Reports Analysis: Sanofi SA (ADR) (NYSE:SNY), XOMA Corp (NASDAQ:XOMA) - share market updates (press release)
06/29/16 06:08 PMCAC 40 Tumbles Lower as Hollande Visits Germany to Discuss the U.K.
06/28/16 11:03 AMGlobal Anti-Adhesion Products Market 2015-2022 - Clinicians and Healthcare Systems: Major Growth Determinants
06/28/16 11:03 AMSanofi Investors Lose Bid To Revive Kickback Allegations
06/28/16 10:35 AMZika vaccines prove 100 percent protective in mice; monkey study shows promise - [Reuters] - Mice given a single shot of one of two experimental Zika vaccines were completely protected when exposed to the virus one to two months later, a promising sign that similar vaccines under development for humans will protect against Zika, U.S. researchers said on Tuesday. "This is an encouraging first step in Zika vaccine design and pre-clinical testing. This new mouse model should be useful for comparative assessments of the large range of vaccine candidates now being designed," said Professor Adrian Hill, director of Oxford University's Jenner Institute, which did not conduct the mouse study but is also developing Zika vaccines.
06/27/16 06:10 PMHow the Asset Swap Deal Fits into Sanofi's Restructuring Plans - Bidness ETC
06/27/16 06:10 PMMedivation Inc Shareholders May Turn Down Sanofi's Bid - Bidness ETC
06/27/16 10:24 AMExperimental Zika vaccine to begin human testing
06/27/16 07:15 AMSanofi Inks Deal to Swap Business with Boehringer Ingelheim -
06/27/16 03:51 AMSanofi to Exit Animal Care in $25 Billion Asset Swap With Boehringer -
06/27/16 12:36 AMSanofi, Boehringer Ingelheim Agree to $25 Billion Asset Swap -
06/26/16 05:15 PMHC Trending Hot Stocks: Immunomedics, Inc. (NASDAQ:IMMU), Sanofi SA (ADR) (NYSE:SNY) - share market updates (press release)
06/24/16 06:21 PMGlass Lewis Backs Medivation Board in Sanofi Dispute
06/23/16 06:54 PMSanofi May Try and Win Over Medivation With Past, Genzyme-Like Tactics - Bidness ETC
06/23/16 08:24 AM$18,543 Invested in This Biotech a Decade Ago Is Now Worth $1 Million -
06/23/16 06:56 AMNew Four-Strain Influenza Vaccine, VaxigripTetra™, Regulatory Dossier from Sanofi Pasteur Now Approved in Europe - [PR Newswire] - LYON, France, June 23, 2016 /PRNewswire/ -- New VaxigripTetra ™ v accine: A 4-strain influenza vaccine for people 36 months of age and older, Helps protect children , adults and seniors against both ...
06/22/16 10:05 PMSanofi Pasteur Dengue Vaccine Approved in Costa Rica - [PR Newswire] - SAN JOSE, Costa Rica, June 23, 2016 /PRNewswire/ -- Today Sanofi Pasteur, Sanofi's vaccine division, announced that the National Ministry of Health of Costa Rica has approved Sanofi Pasteur's tetravalent dengue vaccine, Dengvaxia®, to protect individuals 9 to 45 years of age living in endemic areas against all four serotypes of dengue. This approval in Costa Rica is the fourth registration of the dengue vaccine in Latin America, and the fifth in the world.
06/22/16 06:14 PMCAC 40 Extends Gains as France’s Interior Ministry Reverses Ban on Labour Protests
06/22/16 10:58 AMZika Update: First Zika Vaccine Ready for Human Trial
06/21/16 05:47 PMZika Vaccine Headed For Human Trial
06/21/16 10:35 AMZika Vaccine Approved For Testing In Humans
06/20/16 07:49 AMInovio Pharma gets green signal to test Zika vaccine in human trial
06/18/16 05:26 PMCan BioMarin Rumors be Sanofi's Ruse to Lure In Medivation? - Bidness ETC
06/18/16 10:22 AMVascular Biogenics Ltd (NASDAQ:VBLT) & Sanofi SA (ADR) (NYSE:SNY) Healthcare Stocks to Watch - Wall Street 24
06/17/16 07:07 AMWHO backs cut in yellow fever vaccine dose to eke out supplies -
06/17/16 05:21 AMExperts back plan to stretch yellow fever vaccine supply - WHO -
06/16/16 06:30 PMVisium's Valvani charged with insider trading on FDA leaks
06/16/16 10:35 AMUS charges hedge fund manager Valvani with insider trading
06/16/16 10:35 AMMedivation Prescription Growth And Potential Price Increases Could Drive Upside This Year
06/16/16 10:35 AMFeds charge four in FDA-tip insider trading scheme
06/15/16 06:09 PMSanofi SA (ADR) (NYSE:SNY) & Minerva Neurosciences (NASDAQ:NERV) Stocks Under Review - Wall Street 24
06/15/16 10:46 AMMedivation Slams Sanofi's $9.3B Hostile Takeover Play
06/15/16 10:46 AMOsteoarthritis Treatment Market Key Players' Profile and Industry Analysis to 2021
06/14/16 05:58 PMSanofi SA (ADR), Medivation Inc: Journey to Possible Hostile Takeover Begins - Bidness ETC
06/13/16 09:13 AMSanofi SA Achieves Another Milestone in Diabetes Treatment - Bidness ETC
06/13/16 08:33 AMSanofi files request to replace Medivation board - [Reuters] - French drugmaker Sanofi said on Monday that it had filed a request with U.S. authorities to remove the board of Medivation and replace it with eight independent candidates as it seeks to acquire the cancer ...
06/12/16 02:54 PMSanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide - [PR Newswire] - PARIS, June 12, 2016 /PRNewswire/ -- Sanofi announced today the presentation of the results of the pivotal Phase 3 LixiLan-O and LixiLan-L clinical trials with the investigational titratable fixed-ratio ...
06/11/16 10:01 AMSuccessful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting - [PR Newswire] - PARIS, June 11, 2016 /PRNewswire/ -- Sanofi announced today the release of the new real world data assessing the use of Toujeo® (insulin glargine injection 300 Units/mL). The study examined electronic health records to assess the change in HbA1c (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76th Scientific Sessions in New Orleans, LA, U.S.A.
06/09/16 05:33 AMEU mergers and takeovers (June 9) - [Reuters - UK Focus] - The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- U.S. food service distributor Sysco Corp to acquire UK peer Brakes ...
06/08/16 08:45 AMANTB: Once Weekly Diabetes Therapy: Investors Needed -
06/07/16 06:31 PMSanofi SA, Regeneron Pharmaceuticals Inc. To Launch Blockbuster Molecule Really Soon - Business Finance News
06/07/16 09:00 AMMedivation Inc: Why Sanofi's Offer Does Not Reflect the Company's True Potential - Bidness ETC
06/06/16 06:22 PMSanofi and Regeneron report positive skin disease trial - Channel News Asia
06/03/16 06:53 PMPfizer Inc, Sanofi SA (ADR) Could Eye Biogen's Hemophilia Franchise - Bidness ETC
06/02/16 06:44 PMSanofi SA (EPA:SAN) Given Average Rating of “Hold” by Analysts - Let Me Know About This - Sanofi SA (EPA:SAN) Given Average Rating of “Hold” by AnalystsLet Me Know About ThisSanofi SA logo Shares of Sanofi SA (EPA:SAN) have earned an average recommendation of “Hold” from the sixteen ratings firms that are covering the firm. Two investment analysts have rated the stock with a sell recommendation, nine have assigned a hold ...
06/02/16 06:44 PMSanofi SA Presses Forward On Hostile Takeover Of Medivation - California Healthline - Sanofi SA Presses Forward On Hostile Takeover Of MedivationCalifornia HealthlineMedivation Inc.'s shareholders as of close of business Wednesday will be able to vote on Sanofi SA's proposal to replace the oncology drugmaker's board. San Francisco-based Medivation set Wednesday as the so-called record date, hours after the French ...
06/02/16 06:44 PMSanofi SA May Raise its Medivation Inc Bid “Considerably”: Credit Suisse - Bidness ETC - Bidness ETCSanofi SA May Raise its Medivation Inc Bid “Considerably”: Credit SuisseBidness ETCMedivation Inc. (NASDAQ:MDVN) has designated June 1 as the record date for its shareholders to vote on Sanofi SA's (ADR) (NYSE:SNY) proposal to oust the cancer company's board of directors. After Medivation rejected Sanofi's $9.3 billion takeover offer ...Sanofi asks for cutoff date for Medivation voteMarketWatchSanofi Asks Medivation Set Deadline for Shareholders' Consent to Remove and Replace Medivation Board (NYSE:SNY)Sonoran Weekly Reviewall 30 news articles »
06/01/16 06:51 PMSanofi Asks for Record Date for Vote on Medivation's Board - Wall Street Journal - Wall Street JournalSanofi Asks for Record Date for Vote on Medivation's BoardWall Street JournalFrench pharmaceutical company Sanofi SA SNY -0.15 % on Wednesday pressed forward i ts $9.3 billion hostile takeover bid for Medivation Inc., MDVN 1.12 % asking the oncology drugmaker to set a cutoff date to determine which shareholders would vote on ...and more »
About Sanofi SA

Sanofi SA logoSanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Company's principal activities. Under the Company's Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: EPA
  • Symbol: SAN
  • CUSIP:
Key Metrics:
  • Previous Close: $74.92
  • 50 Day Moving Average: $25.63
  • 200 Day Moving Average: $25.47
  • P/E Ratio: 22.52
  • P/E Growth: 0.00
  • Market Cap: $96.08B
  • Current Quarter EPS Consensus Estimate: $6.30 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha